MX2013014027A - Formulacion liquida estable de etanercept. - Google Patents
Formulacion liquida estable de etanercept.Info
- Publication number
- MX2013014027A MX2013014027A MX2013014027A MX2013014027A MX2013014027A MX 2013014027 A MX2013014027 A MX 2013014027A MX 2013014027 A MX2013014027 A MX 2013014027A MX 2013014027 A MX2013014027 A MX 2013014027A MX 2013014027 A MX2013014027 A MX 2013014027A
- Authority
- MX
- Mexico
- Prior art keywords
- etanercept
- liquid formulation
- stable liquid
- present
- formulation
- Prior art date
Links
- 108010008165 Etanercept Proteins 0.000 title abstract 5
- 229960000403 etanercept Drugs 0.000 title abstract 5
- 239000012669 liquid formulation Substances 0.000 title abstract 4
- 239000006227 byproduct Substances 0.000 abstract 2
- 108091006020 Fc-tagged proteins Proteins 0.000 abstract 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se refiere a una formulación líquida estable de etanercept (proteína de fusión sTNFR:Fc p75 recombinante) y más particularmente a una formulación líquida que comprende uno o más estabilizantes seleccionados del grupo que consiste en metionina, usina, histidina y sales farmacéuticamente aceptables de las mismas en una cantidad suficiente para reducir la formación de subproductos de etanercept durante el almacenamiento. La formulación líquida según la presente invención reduce eficazmente la producción de subproductos de etanercept y mantiene de forma estable su eficacia farmacéutica durante un almacenamiento a largo plazo. Por lo tanto, no se requiere un procedimiento de reconstitución antes de su administración y la formulación estéril puede administrarse a pacientes para garantizar la seguridad del paciente. Así, puede aplicarse a sectores con necesidad de tratamiento con etanercept.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20110053890 | 2011-06-03 | ||
PCT/KR2012/004369 WO2012165917A1 (en) | 2011-06-03 | 2012-06-01 | Stable liquid formulation of etanercept |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013014027A true MX2013014027A (es) | 2014-04-16 |
MX354297B MX354297B (es) | 2018-02-23 |
Family
ID=46690924
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013014027A MX354297B (es) | 2011-06-03 | 2012-06-01 | Formulación líquida estable de etanercept. |
Country Status (26)
Country | Link |
---|---|
US (1) | US10258689B2 (es) |
EP (1) | EP2714009B1 (es) |
JP (2) | JP5918850B2 (es) |
KR (2) | KR101482304B1 (es) |
CN (2) | CN104623656B (es) |
AR (1) | AR086658A1 (es) |
AU (1) | AU2012263100B2 (es) |
BR (1) | BR112013031112A8 (es) |
CA (1) | CA2837176C (es) |
CL (1) | CL2013003461A1 (es) |
CO (1) | CO6852068A2 (es) |
EA (1) | EA028947B1 (es) |
ES (1) | ES2645969T3 (es) |
HK (1) | HK1204921A1 (es) |
HU (1) | HUE037031T2 (es) |
IL (1) | IL229787A (es) |
MA (1) | MA35186B1 (es) |
MX (1) | MX354297B (es) |
MY (1) | MY173907A (es) |
SG (1) | SG195054A1 (es) |
TN (1) | TN2013000493A1 (es) |
TW (2) | TWI548424B (es) |
UA (1) | UA113172C2 (es) |
UY (1) | UY34105A (es) |
WO (1) | WO2012165917A1 (es) |
ZA (1) | ZA201308659B (es) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2610839C (en) | 2005-06-14 | 2019-06-25 | Amgen Inc. | Self-buffering protein formulations |
UY34105A (es) * | 2011-06-03 | 2012-07-31 | Lg Life Sciences Ltd | Formulación líquida estable de etanercept |
MX2014004728A (es) | 2011-10-18 | 2015-05-15 | Coherus Biosciences Inc | Formulaciones de etanercept estabilizadas con cloruro de sodio. |
US10493151B2 (en) | 2011-10-18 | 2019-12-03 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with sodium chloride |
IN2015KN00005A (es) * | 2012-07-09 | 2015-07-31 | Coherus Biosciences Inc | |
PL2892550T3 (pl) | 2012-09-07 | 2020-07-27 | Coherus Biosciences, Inc. | Stabilne wodne formulacje adalimumabu |
LT2895188T (lt) | 2012-09-11 | 2018-04-10 | Coherus Biosciences, Inc. | Aukšto grynumo ir geros išeigos teisingos struktūros etanerceptas |
JP2014214153A (ja) * | 2013-04-30 | 2014-11-17 | ニプロ株式会社 | 水溶液製剤およびその製造方法 |
EP2991668A1 (en) * | 2013-05-02 | 2016-03-09 | Mabxience, S.A. | Alternative formulations for tnfr: fc fusion polypeptides |
WO2015056613A1 (ja) * | 2013-10-15 | 2015-04-23 | Meiji Seikaファルマ株式会社 | 安定化されたポリペプチド水性製剤 |
CN106061468B (zh) * | 2013-11-29 | 2020-10-02 | 阿雷斯贸易股份有限公司 | 包含TNFR和Fc区的融合蛋白的液体制剂 |
TWI694836B (zh) * | 2014-05-16 | 2020-06-01 | 英商葛蘭素史克智慧財產管理有限公司 | 抗體調配物 |
EP3148568A4 (en) * | 2014-05-28 | 2018-01-17 | Nono Inc. | Lyophilized formulation of tat-nr2b9c with acetylation scavenger |
JP6480154B2 (ja) * | 2014-11-06 | 2019-03-06 | 持田製薬株式会社 | エタネルセプトの凍結乾燥製剤 |
ES2833506T3 (es) | 2014-12-22 | 2021-06-15 | Ares Trading Sa | Composición farmacéutica líquida |
US9672719B1 (en) | 2015-04-27 | 2017-06-06 | State Farm Mutual Automobile Insurance Company | Device for automatic crash notification |
CN104940902B (zh) * | 2015-05-29 | 2018-08-10 | 北京凯因科技股份有限公司 | 一种聚乙二醇集成干扰素变异体的稳定溶液 |
KR101808234B1 (ko) * | 2015-06-23 | 2017-12-12 | (주)알테오젠 | IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제 |
WO2017007837A1 (en) * | 2015-07-07 | 2017-01-12 | Nanobio Corporation | Methods and compositions for the stabilizaton of proteins |
MX2015010517A (es) * | 2015-08-13 | 2017-02-13 | Landsteiner Scient S A De C V | Composicion de estabilidad mejorada de etanercept. |
US11229702B1 (en) | 2015-10-28 | 2022-01-25 | Coherus Biosciences, Inc. | High concentration formulations of adalimumab |
US11071782B2 (en) | 2016-04-20 | 2021-07-27 | Coherus Biosciences, Inc. | Method of filling a container with no headspace |
AU2017333367A1 (en) * | 2016-09-27 | 2019-04-04 | Fresenius Kabi Deutschland Gmbh | Liquid pharmaceutical composition |
US20180110856A1 (en) * | 2016-10-21 | 2018-04-26 | Amgen Inc. | Pharmaceutical Formulations and Methods of Making the Same |
EP3533441A4 (en) | 2016-10-28 | 2019-12-04 | Celltrion Inc. | STABLE PHARMACEUTICAL FORMULATION |
MY197202A (en) * | 2017-03-16 | 2023-05-31 | Lg Chemical Ltd | A liquid formulation of anti-tnf alpha antibody |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
EP3618871A4 (en) | 2017-05-02 | 2021-01-06 | Merck Sharp & Dohme Corp. | ANTI-LAG3 ANTIBODIES ETCO-FORMULATIONS ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES |
MX2017013995A (es) * | 2017-10-31 | 2019-05-01 | Probiomed S A De C V | Formulacion farmaceutica estable de una proteina de fusion. |
CA3085158C (en) * | 2017-12-22 | 2023-04-04 | Samsung Bioepis Co., Ltd. | Liquid composition comprising vegf antagonist |
US11253569B2 (en) | 2018-05-03 | 2022-02-22 | Seattle Children's Hospital | Methods of treating Kawasaki Disease |
CN112312890A (zh) * | 2018-05-04 | 2021-02-02 | 伊尔科根医药工业和贸易有限公司 | 稳定的杂合fc融合g-csf制剂 |
MX2021004356A (es) * | 2018-10-18 | 2021-05-31 | Merck Sharp & Dohme Llc | Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas. |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
EP0620739A4 (en) | 1992-09-15 | 1997-01-15 | Immunex Corp | Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists. |
US5358708A (en) * | 1993-01-29 | 1994-10-25 | Schering Corporation | Stabilization of protein formulations |
WO2003009817A2 (en) | 2001-07-25 | 2003-02-06 | Protein Design Labs, Inc. | Stable lyophilized pharmaceutical formulation of igg antibodies |
KR100913714B1 (ko) * | 2001-11-08 | 2009-08-24 | 패시트 바이오테크 코포레이션 | Igg 항체의 안정한 액상 약학 제형물 |
ATE402716T1 (de) | 2002-02-27 | 2008-08-15 | Immunex Corp | Stabilisierte tnfr-fc formulierung mit arginin |
US7132100B2 (en) * | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
EP1654281A1 (en) | 2003-08-01 | 2006-05-10 | Amgen, Inc. | Crystalline tumor necrosis factor receptor 2 polypeptides |
SI21639A (sl) | 2003-12-23 | 2005-06-30 | LEK farmacevtska dru�ba d.d. | Farmacevtski pripravek, ki vsebuje nemicelarne sulfobetaine |
ES2553987T3 (es) | 2003-12-25 | 2015-12-15 | Kyowa Hakko Kirin Co., Ltd. | Preparación farmacéutica de base acuosa estable que contiene anticuerpo |
WO2005082377A1 (ja) * | 2004-03-01 | 2005-09-09 | Ajinomoto Co., Inc. | 抗ヒトTNF-α抗体活性低下抑制剤 |
GT200600031A (es) | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
GB0506708D0 (en) | 2005-04-01 | 2005-05-11 | Queen Mary & Westfield College | Use of calcitonin as combined treatment therapy for the management of inflammatory disease conditions |
DE202005006130U1 (de) | 2005-04-12 | 2005-08-25 | Fasys Bauservice Gmbh | Anordnung zur optischen Warnung vor Fahrdrähten |
AU2007212147A1 (en) | 2006-02-03 | 2007-08-16 | Medimmune, Llc | Protein formulations |
CN101426527A (zh) | 2006-02-03 | 2009-05-06 | 米迪缪尼有限公司 | 蛋白质制剂 |
AU2007260769A1 (en) | 2006-06-14 | 2007-12-21 | Imclone Llc | Lyophilized formulations of anti-EGFR antibodies |
BRPI0806313A2 (pt) * | 2007-01-09 | 2011-09-06 | Wyeth Corp | Formulação de anticorpo anti-il-13; formulação em aerossol de um anticorpo anti-il-13; formulaçãoliofilizada de um anticorpo anti-il-13; composição farmacêutica para o tratamento de um transtorno relacionado a il-13; fabricação de uma composição farmacêutica ; método de tratamento de um transtorno relacionado a il-13; seringa injetável; dispositivo para administração nasal; emplastro transdérmico; bolsa intravenosa; kit compreendendo pelo menos um recipiente; kit; e seringa injetável previamente enchida |
UA107557C2 (xx) * | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
JP2009155329A (ja) * | 2007-12-07 | 2009-07-16 | Kyowa Hakko Kirin Co Ltd | 上皮細胞成長因子受容体ファミリーに対する抗体またはその機能的断片およびそれらを含有する癌を治療するための医薬組成物 |
PE20091174A1 (es) * | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
ES2549877T3 (es) * | 2008-09-07 | 2015-11-02 | Glyconex Inc. | Anticuerpo antiglucoesfingolípido de tipo I extendido, derivados del mismo y utilización |
US20100172862A1 (en) * | 2008-11-28 | 2010-07-08 | Abbott Laboratories | Stable antibody compositions and methods of stabilizing same |
KR101468271B1 (ko) * | 2009-03-19 | 2014-12-03 | 추가이 세이야쿠 가부시키가이샤 | 개량된 항체분자를 함유하는 의약 제제 |
WO2011141926A2 (en) * | 2010-05-10 | 2011-11-17 | Intas Biopharmaceuticals Limited | Liquid formulation of polypeptides containing an fc domain of an immunoglobulin |
WO2012143418A1 (en) | 2011-04-20 | 2012-10-26 | Sandoz Ag | STABLE PHARMACEUTICAL LIQUID FORMULATIONS OF THE FUSION PROTEIN TNFR:Fc |
UY34105A (es) | 2011-06-03 | 2012-07-31 | Lg Life Sciences Ltd | Formulación líquida estable de etanercept |
-
2012
- 2012-05-29 UY UY0001034105A patent/UY34105A/es not_active Application Discontinuation
- 2012-06-01 AR ARP120101960A patent/AR086658A1/es not_active Application Discontinuation
- 2012-06-01 MX MX2013014027A patent/MX354297B/es active IP Right Grant
- 2012-06-01 EA EA201391739A patent/EA028947B1/ru unknown
- 2012-06-01 UA UAA201313759A patent/UA113172C2/uk unknown
- 2012-06-01 WO PCT/KR2012/004369 patent/WO2012165917A1/en active Application Filing
- 2012-06-01 MY MYPI2013702234A patent/MY173907A/en unknown
- 2012-06-01 EP EP12793393.5A patent/EP2714009B1/en active Active
- 2012-06-01 KR KR20120059461A patent/KR101482304B1/ko active IP Right Grant
- 2012-06-01 TW TW101119708A patent/TWI548424B/zh active
- 2012-06-01 BR BR112013031112A patent/BR112013031112A8/pt not_active Application Discontinuation
- 2012-06-01 ES ES12793393.5T patent/ES2645969T3/es active Active
- 2012-06-01 HU HUE12793393A patent/HUE037031T2/hu unknown
- 2012-06-01 US US14/123,704 patent/US10258689B2/en not_active Expired - Fee Related
- 2012-06-01 CN CN201410790992.2A patent/CN104623656B/zh active Active
- 2012-06-01 JP JP2014513452A patent/JP5918850B2/ja active Active
- 2012-06-01 TW TW104108045A patent/TW201540322A/zh unknown
- 2012-06-01 CN CN201280026919.7A patent/CN103619324A/zh active Pending
- 2012-06-01 SG SG2013085758A patent/SG195054A1/en unknown
- 2012-06-01 CA CA2837176A patent/CA2837176C/en active Active
- 2012-06-01 AU AU2012263100A patent/AU2012263100B2/en active Active
-
2013
- 2013-11-19 ZA ZA2013/08659A patent/ZA201308659B/en unknown
- 2013-11-25 TN TNP2013000493A patent/TN2013000493A1/fr unknown
- 2013-12-02 CO CO13282255A patent/CO6852068A2/es not_active Application Discontinuation
- 2013-12-03 IL IL229787A patent/IL229787A/en active IP Right Grant
- 2013-12-03 CL CL2013003461A patent/CL2013003461A1/es unknown
- 2013-12-16 MA MA36575A patent/MA35186B1/fr unknown
-
2014
- 2014-08-29 KR KR20140114550A patent/KR20140122213A/ko not_active Application Discontinuation
-
2015
- 2015-06-08 HK HK15105446.2A patent/HK1204921A1/xx unknown
-
2016
- 2016-01-08 JP JP2016002956A patent/JP2016145192A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TN2013000493A1 (en) | Stable liquid formulation of etanercept | |
PH12015502063A1 (en) | Treatment of pediatric growth hormone deficiency with human growth hormone analogues | |
MX2017012506A (es) | Composicion farmaceutica para la prevencion y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteina de fusion en la cual el peptido que penetra el tejido y la preparacion del factor de crecimiento endotelial antivascular se fusionan. | |
ES2866957T3 (es) | Agente terapéutico del síndrome de Hunter y método de tratamiento | |
NZ608502A (en) | Polypeptides that bind to human complement component c5 | |
SG10201804746WA (en) | Surgical methods employing purified amphiphilic peptide compositions | |
EA201491285A1 (ru) | Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты | |
RU2014101482A (ru) | Способ применения 4-((1r,3s)-6-хлор-3-фенилиндан-1-ил)-1,2,2-триметилпиперазина и его солей в лечении шизофрении | |
JP2013515071A5 (es) | ||
JP2017132791A (ja) | 組み合わせ組成物 | |
EP4368175A3 (en) | Perfusion dosage form | |
PH12015501373A1 (en) | Injectable depot formulation comprising optically active tolvaptan and process of producing the same | |
NZ610487A (en) | Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins | |
JOP20190019A1 (ar) | تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH) | |
US11318148B2 (en) | Preservative-free treprostinil devices | |
So | Improving patient compliance with biopharmaceuticals by reducing injection-associated pain | |
PH12014502494B1 (en) | Parenteral esmolol formulation | |
MX2018013474A (es) | Acidos carboxilicos para aplicacion en la primera infancia. | |
TH151414A (th) | การจัดสูตรของเหลวเอทาเนอเซบต์เสถียร | |
UA85645U (ru) | Способ коррекции локальной лимфокоагуляции при панкреатите | |
RU2013105922A (ru) | МЕТОД ПОЛУЧЕНИЯ АНТИЛЮТЕАЛЬНОЙ КРОВИ - АлК, СПОСОБ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ ПОСЛЕРОДОВЫХ АКУШЕРСКО-ГИНЕКОЛОГИЧЕСКИХ ЗАБОЛЕВАНИЙ У КОРОВ | |
GR20110100037A (el) | Τοπικο αναισθητικο |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HC | Change of company name or juridical status |
Owner name: YUHAN CORPORATION |
|
FG | Grant or registration |